HELENA BENHAM: Open Payments
NPI 1639821473 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,487 in 179 payments from 23 companies in 2025. Trend: 2023 $3,547 · 2024 $3,687 · 2025 $6,487
Food & beverage: $3,374Consulting: $2,616Travel & lodging: $488Education: $9
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 15 | $3,456 |
| ABBVIE INC. | 47 | $860 |
| Janssen Biotech, Inc. | 19 | $381 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 23 | $350 |
| Ardelyx, Inc. | 12 | $250 |
| PFIZER INC. | 15 | $244 |
| Gilead Sciences, Inc. | 8 | $177 |
| QOL Medical, LLC | 6 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $162 |
| Madrigal Pharmaceuticals | 5 | $119 |
Products named: RINVOQ, TREMFYA, XIFAXAN, DUPIXENT, IBSRELA, XELJANZ, Sucraid, LINZESS.
Industry payments across KY — which companies pay providers there.
